The aim of the present study was to test a possible effect of the A218C tryptophan hydroxylase (TPH) gene variant on the antidepressant activity of fluvoxamine in a sample of major and bipolar depressives, with or without psychotic features. Two hundred and seventeen inpatients were treated with fluvoxamine 300 mg and either placebo or pindolol in a double blind design for 6 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject by using a PCR-based technique. No significant finding was observed in the overall sample as well as in the pindolol group, while TPH*A/A was associated with a slower response to fluvoxamine treatment in subjects not taking pindolol (P = 0.001). This effect was independent from the previously reported influence Antidepressant drugs efficacy for major depression treatment is partly under genetic control.
Antidepressant drugs efficacy for major depression treatment is partly under genetic control. [1] [2] [3] [4] [5] [6] [7] Selective serotonin reuptake inhibitors (SSRIs) exert their activity through a blockade of the neuronal serotonin transporter. The gene encoding for this protein has been shown to have a functional polymorphism in the upstream regulatory region (5-HTTLPR) 8, 9 and recent studies have reported an association between this polymorphism and the antidepressant response to certain SSRIs, such as fluvoxamine 10, 11 and paroxetine. 12, 13 The variance accounted for by this gene was about 7%. This is in accordance with current views on polygenic inheritance, where minor effect genes contribute only 1-10% to the total phenotypic variance, 14, 15 and the existence of other genes, that contribute with additive, multiplicative or epistatic effects, is very likely. 16 Further candidate genes may then be identified in the serotonin pathway. Tryptophan (TRP) availability influences 5-HT synthesis in the brain, and TRP has been used both alone 17 and in combination with antidepressant drugs 18, 19 for the treatment of major depressive disorders. Moreover rapid TRP depletion in depressed patients in clinical remission causes a transient depressive relapse. 20 The tryptophan hydroxylase (TPH) gene, which codes for the rate-limiting enzyme of serotonin biosynthesis, is therefore a strong candidate for a possible genetic influence on the antidepressant response. This gene has been cloned 21 and mapped on 11p15.3-p14. 22 Two biallelic polymorphisms in complete disequilibrium have been identified on position 218 (A218C) and 779 (A779C) of intron 7. 23 Preliminary evidence suggests that the rarer TPH*A variant influences serotonin turnover as lower CSF 5-HIAA levels were found in male healthy volunteers with the TPH*A allele. 24 The aim of the present paper is to investigate the possible effect of TPH variants both alone and in interaction with 5-HTTLPR on the outcome of fluvoxamine antidepressant treatment.
A detailed description of the clinical outcome of the sample has been separately reported in previous studies. 10, 11 A brief description of the pooled sample is illustrated in Table 1 . The time course of fluvoxamine response was investigated using RRM analysis (Table  2) . We observed a significant effect of time, indicating an overall symptomatological improvement during the trial. The presence of delusional features was associated with higher HAM-D baseline scores, while the remaining variables were not associated with baseline scores. Following this, we performed an analysis on the effect of independent variables on the HAM-D time course. Gender, education, diagnosis and age at onset did not significantly influence antidepressant outcome. Subjects with psychotic features showed a more rapid decrease of depressive symptomatology independently from treatment (P = 0.014). A more rapid improvement was observed in subjects with more severe basal HAM-D score (P Ͻ 0.001). Subjects with pindolol augmentation showed a significantly better response compared to fluvoxamine plus placebo (P = 0.041).
Baseline clinical and demographic characteristics of subjects grouped according to TPH variants did not show any significant difference (Table 1) . No significant association with time course was observed in the overall sample as well as in the pindolol group, on the other hand the TPH*A/A variant was significantly associated with a slower response to fluvoxamine treatment in subjects not taking pindolol (see also Figure  1 ). In fact we observed a significant interaction between TPH variants and pindolol (interaction term: Z = 2.82, P = 0.005), with a much greater effect of TPH variants in subjects without pindolol (TPH effect: Z = −3.21, P = 0.001). We then evaluated the possible confounding effect of clinical variables. In detail, there was a significant interaction between TPH variants and diagnoses (Z = 2.16, P = 0.030), with a greater effect of TPH variants when diagnosis was included in the model (Z = −2.68, P = 0.007), due to a more marked effect in Molecular Psychiatry major depressives. Baseline HAM-D scores, fluvoxamine plasma levels or the presence of psychotic features did not significantly influence the association of TPH with outcome (data not shown). Finally, in order to investigate a possible interaction of TPH and 5- Figure 1 The time course of response divided by TPH variants: subjects with TPH*A/A variant showed a slower decrease of the symptomatology (P = 0.001). This effect was not present in subjects on pindolol.
HTTLPR, we included both polymorphisms in the RRM model considering only subjects not taking pindolol. The interaction was not significant (Table 2 ). In Figure 2 the antidepressant outcome is divided into all possible combinations of the two polymorphisms, the visual inspection suggests an additive effect with independent influences of both polymorphisms. The sample was in Hardy-Weinberg equilibrium ( 2 = 0.006, P = 0.94). It was previously reported that the 5-HTTLPR short variant was associated with a slower response to various antidepressant treatments 10, 12, 13, 25 and that the addition of pindolol to fluvoxamine was able to reduce this genotype effect. In the present sample, subjects with the TPH*A/A variant showed the slowest response, as measured by the HAM-D scores. Also in this case the variant effect was not significant in the group of patients on pindolol augmentation treatment.
We observed a more marked influence of TPH variants on major depressives response. This could be due to the supposedly different genetic background between the two disorders. 26, 27 Recently Kim et al published a study in which the 5-HTTLPR*1/1 was associated with a poor outcome to various SSRIs. 28 However some differences between this and other studies should be pointed out. Firstly from a genetic point of view, polymorphism frequencies in oriental populations are strongly different from those in Western countries, 29 a difference reflected in the samples of the aforementioned paper (frequency of 5-HTTLPR*1 in normals 0.25 vs 0.58-0.68 in Western countries). Subsequently the number of 1/1 patients in the sample was low (n = 5). Last but not least the use of a different response criterion (50% HAM-D score decrease vs a final score of 8) further complicates any comparison. However a more recent paper reported an association between 5-HTTLPR and paroxetine response in the same direction as our original paper. 13 The frequencies of TPH alleles and genotypes in our sample were similar to those published for Western countries, being 0.57 and 0.43 for the TPH*C and TPH* A allele, respectively. They did not significantly differ from the ones, 0.60 and 0.40, in Nielsen et al. 23, 30 Ethnic origin is a possible cause of stratification bias since a significant TPH allele frequency variation has been reported among samples of individuals from populations in different parts of the world. 31 However, Italy being characterized by a substantial genetic homogeneity, 32 we tend to exclude such bias from our sample. The frequencies in this study were different from those found by Bellivier et al. 33 This was the only report where an overall association of TPH*A with bipolar disorder was observed while several others failed to confirm this finding. [34] [35] [36] [37] [38] [39] [40] TPH variants have also been associated with alcoholism, 41 but further rare variants did not prove to be associated with either mood and anxiety disorders. [42] [43] [44] To date, no definite information is available about the possible functional consequences of the TPH A218C polymorphism. It is located in a potential GATA transcription factor binding site and therefore might affect TPH gene expression. 23 Alternatively, it may be in linkage disequilibrium with another nearby functional mutation. Recently, lower CSF 5-HIAA levels were found in male healthy volunteers with the TPH*A allele. 24 The TPH*A variant was also proposed as a liability factor for suicidal behavior (though not unequivocably), 35, 39, [45] [46] [47] [48] [49] [50] and anger-related traits. 51, 52 The TPH polymorphism explained about 5% of the variance (effect size f = 0.235) of the variation in antidepressant efficacy, 53 an observation that could be in agreement with a supposedly minor effect of the gene coding for the TPH. Moreover, the effect proved to be independent from that of the 5-HTTLPR, thus suggesting an additive effect. The antidepressant drugs activity could be mediated by two limiting steps, one at the level of the TPH and the second at the level of 5-HT transporter function. In conclusion, variants of Molecular Psychiatry the TPH polymorphism, as well as those of the 5-HTTLPR, may influence the antidepressant response to fluvoxamine, particularly the onset of action. In both cases, pindolol appears to be able to override these genetic effects, therefore it is mainly recommended in those subjects displaying unfavorable variants (TPH* A/A and 5-HTTLPR*s/s). If confirmed by future studies, these results could turn out to be a useful tool for the clinician in choosing a proper pharmacological treatment for each patient.
Methods

Sample
Two hundred and seventeen inpatients, consecutively admitted to the Mood Disorder Center, Department of Psychiatry at the Institute H San Raffaele, Milan, were included in this study (age = 52.11 ± 12.04 years; onset = 37.97 ± 12.16 years; female/male: 144/73; bipolars: delusional/non delusional = 40/33, major depressives: delusional/non delusional = 71/73). Lifetime diagnoses were assigned by trained psychiatrists and supervised by an independent senior psychiatrist on the basis of unstructured clinical interviews and medical records, according to DSM-IV criteria 54 and following a best estimate procedure. 55 The presence of any concomitant Axis I diagnosis, major depressive single episode, together with somatic or neurological illnesses impairing psychiatric evaluation represented exclusion criteria. Subjects had not taken nonreversible monoamine oxidase inhibitors or slow-release neuroleptics for at least one month before entering the study.
All patients were evaluated at baseline and weekly thereafter until the sixth week using the 21-item Hamilton Rating Scale for Depression (HAM-D-21) 56 administered by trained senior psychiatrists blind to genetic data and to treatment. Subjects for the present study have been treated in the context of two previous trials under double blind conditions 10, 11 where 5-HTTLPR variants were studied. The procedure was the same in both trials. Briefly, after a 7-day washout period, fluvoxamine was titrated to reach 300 mg daily from day 8 until the end of the trial. Pindolol 2.5 mg three times a day was blindly added to approximately half of the sample randomly selected (96/217). Concomitant psychotropic drugs were not allowed, except flurazepam at bedtime (up to 45 mg) or lithium maintenance (n = 26/217). A decrease in HAM-D scores to 8 or less, with Delusion factor equal to 0 (items 2, 15, 20), [57] [58] [59] was considered the response criterion. After the procedure had been fully explained to all subjects, informed consent was obtained.
Plasma fluvoxamine levels were determined by highperformance liquid chromatography after 2 weeks of stable 300 mg daily dose. 60 Nine patients with fluvoxamine plasma levels exceeding the mean value of the sample ± 1.96 SD were removed from the study to avoid the possibility that extreme differences in the bioavailability of the drug could influence the clinical response.
DNA analysis DNA was extracted from leucocytes by NaCl precipitation. 61 Genomic DNA was extracted from leucocytes by NaCl precipitation. 61 For PCR the 5Ј-TTC AGA TCC CTT CTA TAC CCC AGA-3Ј and 5Ј-GGA CAT GAC CTA AGA GTT CAT GGC A-3Ј primers were employed. 33 The PCR reaction was carried out in a 10-l volume containing 150 ng genomic DNA, 1 M of each primer, 200 M each dNTP, 1× PCR buffer (Perkin Elmer Italia, Monza, Italy), 5% of DMSO and 0.025 U l −1 of Taq Polymerase (Perkin Elmer Italia). After an initial denaturation step of 4 min at 99°C, 35 cycles of amplification (30 s at 94°C, 30 s at 60°C, 30 s at 72°C) and a final extension step of 2 min at 72°C were performed. An aliquot of PCR product was digested using BfaI (New England BioLabs, Beverly, MA, USA) and the fragments obtained were separated in 2.5% agarose gels. Depending on the presence or absence of the polymorphic BfaI site, either one fragment (allele A) or two fragments (allele C) were produced. 5-HTTLPR polymorphism analysis was carried out with primers and conditions as described elsewhere. 10 
Statistical analysis
Seven HAM-D scores' measurements (baseline and 6 weeks) were analyzed. Common methods of analysis of longitudinal data imply some level of oversimplification (for a complete review see Gibbons et al 62 ). Repeated measures analysis of variance on weekly based mean scores is the most common technique, but two drawbacks are present: first, it does not take into account interindividual variability and second, it is based on an a priori assumption of equal weekly variances. When analyzing longitudinal data, not only the mean trend is of interest, but also the distribution of trends in the sample. To accomplish this analysis, a random regression model (RRM) has been developed, which demonstrates considerably superior flexibility and power when compared to traditional techniques [62] [63] [64] RRM used for the present study was implemented with the computer program MIXREG available at http://www.uic.edu/ෂhedeker/mix.htm. 65 In the RRM, we included the HAM-D total scores as dependent variables, time and intercept as random effects, and each independent variable plus the interaction with time as fixed effects. In order to obtain an approximate linearity we used the transformation Ln (time + 1). When multiple independent variables were included in the model they were added with the interaction factor with time. The baseline score was included in the model, as well as all the clinical variables that were associated with outcome when investigating TPH variants. An 'intent-to-treat' analysis was carried out for all patients who had a baseline assessment and at least one assessment after randomization, with the last observation carried forward on the HAM-D. A Student's t-test and chi-square were used when appropriate. All P values were 2-tailed, and statistical significance was set at P Ͻ 0.05.
